CHATTEM LAUNCHING MAXIMUM STRENGTH FLEX-ALL 454, supported by $ 3 mil.-worth of television ads beginning Oct. 1, the company said. Handled by the Los Angeles-based agency Peachtree Creek, the TV spots will feature professional athletic trainers and former New York Jets quarterback Joe Namath, who has served as spokesperson for the Flex-All 454 brand. The new topical analgesic gel contains 16% menthol in an aloe vera base, which Chattem calls the "maximum dosage allowable." Flex-All 454 contains 7% menthol. Couponing for Maximum Strength Flex-All 454 will include over 55 mil. 50 " coupons to be distributed starting Oct. 31. Overall, Chattem expects to drop approximately 70 mil. coupons for the gel beginning in September. In July, Chattem plans to begin shipping the product to the trade along with three displays offering $ 1.50 rebates. Maximum Strength Flex-All 454 will come in two sizes, 1.5 ounces and 3 ounces, with a cost to retail of $ 2.70 per 1.5-ounce bottle and $ 4.05 per three-ounce bottle. A Maximum Strength Flex-All 454 floorstand display will carry 27 three-ounce packages, while a "sidekick" display will contain 24 three-ounce packages. A 12-piece counter display will include eight 1.5-ounce packages and four three-ounce packages. Based on consumer testing by over 500 topical analgesic users, Chattem claims that Maximum Strength Flex-All 454 "absorbs quickly," "penetrates deeply," "works fast," "provides soothing sensation," "helps relax muscles," and "provides long-lasting relief," according to promotional materials. Packaging for the new product emphasizes that it is "greaseless," "stainless" and has a "vanishing scent." Chattem said that Maximum Strength Flex-All 454 can be used to alleviate arthritis, tendonitis, bursitis, backaches, strains and sprains. Chattem estimated the topical analgesic market -- including Pfizer's Ben-Gay, Thompson Medical's Aspercreme, and Chattem's Icy Hot -- at around $ 200 mil. The firm noted that Flex-All 454 was the "largest-selling product" in its category for 1992 on the strength of a 27% sales increase, and was the most heavily advertised product in the category during 1990-1992.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
A government-backed program is working on improving the ability to run dementia clinical trials in the UK, and access to trials for participants.
Vinay Prasad’s exit from the US FDA reignited conversations about integrating its drugs and biologics centers under George Tidmarsh. Those plans appear to be shelved, but the leadership transition could be an opportunity to fully realize the vision for the Oncology Center of Excellence.
The Pink Sheet viewed Stealth's complete response letter and other documents indicating the FDA appears willing to grant accelerated approval to elamipretide before a confirmatory trial begins enrolling. But the company says it needs a two-month review of the NDA resubmission to survive.
